Topical formulations comprising one or more cannabinoids, one or more terpenes, and one or more flavonoids; and methods and uses thereof for the treatment of an integumentary wound, wherein the one or more cannabinoids comprise tetrahydrocannabinolic acid.

The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in methods of treating disease and for imaging of disease.

The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (−)-trans-tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (−)-cis tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (−)-trans-THC. The cannabinoid (−)-cis-THC has been found to occur in low concentrations in particular cannabis plant strains which have been bred to produce cannabidiol (CBD) as the dominant cannabinoid. Furthermore, the cannabinoid can be produced by synthetic means.

The present invention relates to a tetrahydrocannabinol (THC) type cannabinoid compound for use as a medicament. The THC-type cannabinoid is an enantiomer of the (−)-trans-tetrahydrocannabinol which is a naturally occurring cannabinoid that can be found in cannabis plant strains which have been bred to yield THC as the dominant cannabinoid. The particular enantiomer (−)-cis tetrahydrocannabinol has been found to have properties which are different from the naturally occurring (−)-trans-THC. The cannabinoid (−)-cis-THC has been found to occur in low concentrations in particular cannabis plant strains which have been bred to produce cannabidiol (CBD) as the dominant cannabinoid. Furthermore, the cannabinoid can be produced by synthetic means.

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

The present disclosure relates to new cannabinoid derivatives and precursors and processes for their preparation. The disclosure also relates to pharmaceutical and analytical uses of the new cannabinoid derivatives.

A method of selectively recovering a hydrophobic target substance. The method is applied to a solution of the target substance in a hydrophobic solvent. An insoluble polysaccharide is combined with the solution, the solution is passed over the insoluble polysaccharide or otherwise exposed to the insoluble polysaccharide. A hydrophilic solvent, which is less hydrophobic than the hydrophobic solvent, is combined with the solution or combined with the hydrophobic target substance and the insoluble polysaccharide after evaporation of the hydrophobic solvent to facilitate binding of the insoluble polysaccharide with the target substance rather than remaining in solution in the hydrophobic solvent. The cyclic polysaccharide is isolated from the solution. A dissociation solvent is combined with the cyclic polysaccharide for solubilizing the target substance from the cyclic polysaccharide and recovering the target substance.

A method of selectively recovering a hydrophobic target substance. The method is applied to a solution of the target substance in a hydrophobic solvent. An insoluble polysaccharide is combined with the solution, the solution is passed over the insoluble polysaccharide or otherwise exposed to the insoluble polysaccharide. A hydrophilic solvent, which is less hydrophobic than the hydrophobic solvent, is combined with the solution or combined with the hydrophobic target substance and the insoluble polysaccharide after evaporation of the hydrophobic solvent to facilitate binding of the insoluble polysaccharide with the target substance rather than remaining in solution in the hydrophobic solvent. The cyclic polysaccharide is isolated from the solution. A dissociation solvent is combined with the cyclic polysaccharide for solubilizing the target substance from the cyclic polysaccharide and recovering the target substance.

A polymer for liquid chromatography or solid phase extraction is provided. The polymer is prepared by polymerizing styrene and divinylbenzene to form a styrene-divinylbenzene copolymer; soaking the styrene-divinylbenzene copolymer in a swelling agent to form nano-scale micropores; and soaking the microporous styrene-divinylbenzene copolymer in methanol. When packed in a chromatographic column, the polymer can be used to produce produce natural health or medicinal products from Cannabis species, for example, industrial hemp.

A polymer for liquid chromatography or solid phase extraction is provided. The polymer is prepared by polymerizing styrene and divinylbenzene to form a styrene-divinylbenzene copolymer; soaking the styrene-divinylbenzene copolymer in a swelling agent to form nano-scale micropores; and soaking the microporous styrene-divinylbenzene copolymer in methanol. When packed in a chromatographic column, the polymer can be used to produce produce natural health or medicinal products from Cannabis species, for example, industrial hemp.